Pramlintide vs Retatrutide
A side-by-side research comparison of Pramlintide and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Pramlintide | Retatrutide |
|---|---|---|
| Full name | Pramlintide (Symlin) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | Phase 3 Clinical Trial |
| Mechanism | Mimics amylin by activating amylin receptors, which slows gastric emptying, suppresses inappropriate glucagon secretion after meals, and increases satiety - complementing insulin's effects. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 3949.4 Da | 5,200 Da (approximate) |
| Half-life | ~48 minutes | 6 days |
| Bioavailability | Subcutaneous injection | High (SubQ) |
| Typical dose | 15-120 mcg before meals | 1-2 mg → titrate up to 12 mg |
| Frequency | Before major meals | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Pramlintide reported benefits
- Appetite suppression and satiety
- Slows gastric emptying
- Improves post-meal glucose control
- Modest weight loss
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.